- Home
- ANNX vs MFIN Comparison
ANNX vs MFIN Comparison
Compare ANNX & MFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- MFIN
- Stock Information
- Founded
- ANNX 2011
- MFIN 1995
- Country
- ANNX United States
- MFIN United States
- Employees
- ANNX N/A
- MFIN N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- MFIN Finance: Consumer Services
- Sector
- ANNX Health Care
- MFIN Finance
- Exchange
- ANNX Nasdaq
- MFIN Nasdaq
- Market Cap
- ANNX 263.3M
- MFIN 223.8M
- IPO Year
- ANNX 2020
- MFIN 1996
- Fundamental
- Price
- ANNX $2.42
- MFIN $10.46
- Analyst Decision
- ANNX Strong Buy
- MFIN Strong Buy
- Analyst Count
- ANNX 4
- MFIN 1
- Target Price
- ANNX $12.50
- MFIN $12.00
- AVG Volume (30 Days)
- ANNX 1.7M
- MFIN 65.9K
- Earning Date
- ANNX 08-11-2025
- MFIN 07-30-2025
- Dividend Yield
- ANNX N/A
- MFIN 4.47%
- EPS Growth
- ANNX N/A
- MFIN N/A
- EPS
- ANNX N/A
- MFIN 1.75
- Revenue
- ANNX N/A
- MFIN $331,959,000.00
- Revenue This Year
- ANNX N/A
- MFIN N/A
- Revenue Next Year
- ANNX N/A
- MFIN $5.67
- P/E Ratio
- ANNX N/A
- MFIN $6.13
- Revenue Growth
- ANNX N/A
- MFIN 15.99
- 52 Week Low
- ANNX $1.29
- MFIN $7.21
- 52 Week High
- ANNX $7.85
- MFIN $10.98
- Technical
- Relative Strength Index (RSI)
- ANNX 47.32
- MFIN 59.89
- Support Level
- ANNX $2.29
- MFIN $9.87
- Resistance Level
- ANNX $2.62
- MFIN $10.98
- Average True Range (ATR)
- ANNX 0.17
- MFIN 0.42
- MACD
- ANNX -0.01
- MFIN 0.07
- Stochastic Oscillator
- ANNX 37.74
- MFIN 59.76
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.